For high-quality development, inclusive green growth (IGG) is a crucial strategic option. Given the deceleration in economic growth, monetary policy has several obligations, including stabilizing growth, changing structure, and mitigating risks. However, frequent revisions of monetary policy may diminish its regulatory efficacy due to resulting uncertainty. Accordingly, this study reveals the mechanism of the impact of monetary policy uncertainty (MPU) on IGG. Research suggests that MPU significantly inhibits IGG in the region, as demonstrated by robustness tests. Mechanism test reveal that MPU inhibits IGG by reducing green finance, ecological innovation, media attention, and employment levels. These four transmission mechanisms all show a masking effect. Additionally, further tests show that under different levels of green finance, ecological innovation, media attention, and employment, the impact of MPU on IGG is nonlinear. Heterogeneity analyses also indicate that the inhibition of MPU is weaker in cities with high scientific and technological progress and local fiscal expenditure. Finally, quantile regression demonstrates that the restraining effect of MPU diminishes before rising. This study contributes to the advancement of MPU research, provides a solid foundation for formulating, modifying, and executing monetary policy, and serves as a valuable resource for promoting IGG.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11356-023-29076-6 | DOI Listing |
Appl Health Econ Health Policy
December 2024
Health Systems and Health Economics, School of Public Health, Curtin University, Bentley, Perth, Australia.
Background: Women's preferences for time allocation reveal how they would like to prioritise market work, family life, and other competing activities. Whilst preferences may not always directly translate to behaviour, they are an important determinant of intention to act.
Objective: We present the first study to apply a discrete choice experiment (DCE) to investigate time allocation preferences among women diagnosed with breast cancer and women without a cancer diagnosis.
BMC Health Serv Res
December 2024
Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, 10400, Thailand.
No cost-effectiveness information of preventive strategies for mother-to-child transmission (MTCT) of hepatitis B virus (HBV) has existed for policy decision making. This study aimed to compare the cost-effectiveness of alternative strategies to prevent MTCT of HBV in Vietnam. Cost-utility analysis using a hybrid decision-tree and Markov model were performed from healthcare system and societal perspectives.
View Article and Find Full Text PDFMed Decis Making
December 2024
Department of Health Policy, Stanford School of Medicine, Stanford, CA, USA.
Purpose: Individual-level state-transition microsimulations (iSTMs) have proliferated for economic evaluations in place of cohort state transition models (cSTMs). Probabilistic economic evaluations quantify decision uncertainty and value of information (VOI). Previous studies show that iSTMs provide unbiased estimates of expected incremental net monetary benefits (EINMB), but statistical properties of iSTM-produced estimates of decision uncertainty and VOI remain uncharacterized.
View Article and Find Full Text PDFInt J Clin Pharm
December 2024
School of International Pharmaceutical Business, China Pharmaceutical University, No. 639 Longmian Road, Jiangning District, Nanjing, 211198, Jiangsu, China.
Background: Temporal discounting, the preference for immediate over delayed rewards, affects decision-making in domains like health and finance. Understanding the differences in how people discount health outcomes compared to monetary rewards is crucial to shaping health policy and technology assessments.
Aim: This systematic review and meta-analysis aimed to compare temporal discounting parameters between health outcomes and monetary rewards and evaluate their overall relationship.
Am J Geriatr Psychiatry
November 2024
Department of Bioethics (CRM, SH, SYK), Clinical Center, National Institutes of Health Clinical Center, Bethesda, MD. Electronic address:
Objective: The new antiamyloid medications Lecanemab (Leqembi) and donanemab (Kisunla) are the first disease-modifying treatments for Alzheimer's disease (AD) to receive full FDA approval. However, some commentators question whether the drugs' benefits outweigh their risks, burdens, and costs to patients. This study assessed the perceived value of these medications by asking caregivers of persons with AD to compare them to a widely used intervention in AD management: home-based care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!